Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20969493 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ATGFBR1TSHR | |
| SCHEMBL30597491 | 0.73 | MEN1 (0.49) | ALDH1A1MEN1KMT2ATGFBR1TSHR | |
| SCHEMBL7666958 | 0.72 | MEN1 (0.47) | ALDH1A1MEN1KMT2ATGFBR1TSHR | |
| SCHEMBL5683303 | 0.72 | MEN1 (0.47) | ALDH1A1MEN1KMT2ATGFBR1TSHR | |
| SCHEMBL21673038 | 0.72 | MEN1 (0.47) | ALDH1A1MEN1KMT2ATGFBR1TSHR | |
| SCHEMBL1244477 | 0.72 | MEN1 (0.47) | ALDH1A1MEN1KMT2ATGFBR1TSHR | |
| SCHEMBL7700637 | 0.70 | TSHR (0.40) | ALDH1A1MEN1KMT2ATGFBR1TSHR | |
| SCHEMBL20969207 | 0.70 | MEN1 (0.40) | ALDH1A1MEN1KMT2ATGFBR1NFE2L2 | |
| SCHEMBL8330697 | 0.68 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ATGFBR1TSHR | |
| SCHEMBL20969197 | 0.64 | TGFBR1 (0.33) | ALDH1A1MEN1KMT2ATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127306-A1 | POLYCYCLIC CARBOGENIC MOLECULES AND USES THEREOF AS ANTI-CANCER AGENTS | NORTHWESTERN UNIVERSITY (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127306-A1 | POLYCYCLIC CARBOGENIC MOLECULES AND USES THEREOF AS ANTI-CANCER AGENTS | MYC, CDK4, CDKL3 | ALDH1A1 2424/4885MEN1 1952/4885KMT2A 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.